[1]周　琰,王蓓丽,张春燕,等.消化道肿瘤患者MTHFR 基因多态性与5- 氟尿嘧啶化疗不良反应的相关性研究[J].现代检验医学杂志,2020,35(03):1-5.[doi:10.3969/j.issn.1671-7414.2020.03.001]
　ZHOU Yan,WANG Bei-li,ZHANG Chun-yan,et al.Relationship between MTHFR Gene Polymorphisms and Adverse Events by 5-FU in Gastrointestinal Cancer[J].Journal of Modern Laboratory Medicine,2020,35(03):1-5.[doi:10.3969/j.issn.1671-7414.2020.03.001]
点击复制

消化道肿瘤患者MTHFR 基因多态性与5- 氟尿嘧啶化疗不良反应的相关性研究 ()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第35卷
期数:
2020年03期
页码:
1-5
栏目:
论著
出版日期:
2020-07-20

文章信息/Info

Title:
Relationship between MTHFR Gene Polymorphisms and Adverse Events by 5-FU in Gastrointestinal Cancer
文章编号:
1671-7414（2020）03-001-06
作者:
周　琰1;  王蓓丽1; 2; 张春燕1; 2; 潘柏申1; 2; 郭　玮1; 2
（1. 复旦大学附属中山医院检验科，上海　200032；2. 复旦大学附属中山医院厦门医院检验科，福建厦门　361015）
Author(s):
ZHOU Yan1;  WANG Bei-li1; 2;  ZHANG Chun-yan1; 2;  PAN Bai-shen1; 2;  GUO Wei1; 2
（1. Department of Laboratory Medicine, Zhongshan Hospital of Fudan University, Shanghai 200032, China；… 2. Department of Laboratory Medicine, Xiamen Branch, Zhongshan Hospital of Fudan University,Fujian Xiamen. 361015, China）
关键词:
5- 氟尿嘧啶; 亚甲基四氢叶酸还原酶（MTHFR）; 基因多态性; 不良反应
分类号:
R735；R730.43
DOI:
10.3969/j.issn.1671-7414.2020.03.001
摘要:
目的　在消化道肿瘤患者中，探讨MTHFR 1298A>C 和MTHFR 677C>T 基因多态性与5- 氟尿嘧啶（5-FU） 化疗出现不良反应的关系。方法　2016 年2~6 月，入组复旦大学附属中山医院肿瘤内科收治的123 例消化道肿瘤患 者。提取外周血中的基因组DNA，通过Sanger 测序检测MTHFR 1298A>C 和MTHFR 677C>T 的基因型。随访其中 98 例含5-FU 治疗方案的患者，分析了不同基因型的患者发生毒副反应的类型及严重程度的区别。结果　123 例消化道 肿瘤患者中，MTHFR 1298A>C 野生型 76 例（61.79%），杂合型AC 40 例（32.52%），纯合型CC 7 例（5.69%）。 MTHFR677C>T 野生型CC 50 例（40.65%）， 杂合型CT 61 例（49.59%）, 纯合型TT 12 例（9.76%）。98 例化疗 方案中含5-FU 的患者中，MTHFR 677C>T 突变型（CT 和TT）显著增加化疗后发生不良反应的风险（χ2=4.188， P<0.05）；MTHFR 1298A>C 突变型（AC 和AA）、性别、年龄、治疗方案与使用5-FU 产生的相关毒副作用无显著关 联性。结论　在接受5-FU 治疗的消化道肿瘤患者中，MTHFR 677C>T 多态性显著增加化疗相关毒副反应的发生风险， 该基因可能成为预测氟尿嘧啶类化疗药物发生临床不良事件的风险因素，能够为临床选择合适的治疗方案提供更多的信 息。
Abstract:
Objective　To investigate the relationship of MTHFR 677C>T and MTHFR 1298A>C gene polymorphisms in 5-fluorouracil (5-FU)-based chemotherapy in gastrointestinal cancer. Methods　From February 2016 to June 2016, 123 gastrointestinal cancer patients were admitted to Zhongshan Hospital of Fudan University. Genomic DNA in peripheral blood was extracted, and MTHFR 1298A>C, MTHFR677C>T gene polymorphisms were detected by Sanger sequencing. A total of 98 patients treated with 5-FU were chosen to observe the adverse events during chemotherapy, and the differences between the adverse event and grades in patients with different genotypes was analyzed. Results　Of the 123 patients, MTHFR 1298A>C wild type AA was 76 (61.79%), heterozygous AC was 40 (32.52%) and homozygous CC was 7 (5.69%). MTHFR 677C>T wild type CC was 50 cases (40.65%), heterozygous type CT was 61 cases (49.59%) and homozygous type TT 12 was cases (9.76%). In the 98 gastrointestinal Cancer cases, the incidence of total the incidence of adverse events in the patients carrying the MTHFR 677C>T (CT+TT) genotype was higher than in the WT genotype (CC) (P<0.05). The MTHFR 1298A>C genotype, sex, age and chemotherapy strategy were not associated with the adverse events inducing by 5-FU. Conclusion　The MTHFR 677C>T polymorphism significantly increases the risk of chemotherapy-related adverse reactions in gastrointestinal cancer patients treated with 5-FU.The applying of MTHFR polymorphism may be used as a risk factor for predicting clinical adverse events in fluorouracil-based chemotherapy and assist the individualized treatment in gastrointestinal cancer.

参考文献/References:

[1]　 PULLARKAT S T, STOEHLMACHER J, GHADERI V, et al. Thymidylate synthase gene polymorphism det ermi n es response a n d toxici ty of 5-FU chemotherapy[J]. Pharmacogenomics Journal, 2001, 1(1):65-70.
[2]　 K?HNE C, CUNNINGHAM D, DICOSTANZO F, et al. Clinical determinants of tumor response in patients with 5-FU based treatment for metastatic colorectal cancer. Results of a multivariate analysis of 3 825 patients[J]. European Journal of Cancer, 2001, 37(supp1 6):S272.
[3]　 沈玲, 罗波. 晚期胃癌二线使用EOX 和FOLFIRI 方 案化疗的疗效及安全性评价[J]. 西安交通大学学报 ( 医学版), 2018, 39(4):546-550. 　　 SHEN Ling，LUO Bo. Efficacy and safety of secondline chemotherapy with EOX and FOLFIRI in advanced gastric cancer [J].Journal of Xi’an Jiaotong University(Medical Sciences) , 2018, 39(4):546-550.
[4]　 朱铁峰, 崔贵, 景凯, 等. ERCC1, RRM1, TYMS, TUBB3 表达对晚期非小细胞肺癌个体化治疗的应 用分析[J]. 中国临床研究, 2015, 28(6):736-739. 　　 ZHU Tiefeng, CUI Gui, JING Kai, et al. Expression of ERCC1, RRM1, TYMS and tubb3 in the treatment of advanced non-small cell lung cancer[J]. Chinese Journal of Clinical Research, 2015, 28(6):736-739.
[5]　 EISENTHAL A, EYTAN K, BRAZOWSKI E, et al. Effects of 5-FU on DNA synthesis and cytotoxicity of human lymphocytes induced by IL-2, TGF-beta3 and PGE2[J]. Anticancer Research, 2009, 29(10):3925- 3930.
[6]　 王莹, 孟猛. 奥沙利铂联合不同使用方法5-FU/FA 方案治疗晚期结直肠癌的疗效及不良反应对比[J]. 中外医疗, 2018, 37(2):7-9. 　　 WANG Ying, MENG Meng. Comparison of curative effect and adverse reactions of oxaliplatin com-bined with different use methods 5-FU/FA plans in treatment of advanced colorectal cancer [J]. China Foreign Medical Treatment, 2018, 37(2):7-9.
[7]　　 VAN HALTEREN H K, ROUMEN R M, COEBERGH J W, e t a l . The impact of 5-FU-based bolus chemotherapy on survival in patients with advanced colorectal cancer[J]. Anticancer Research, 1999, 19(4C):3447-3449.
[8]　　 HEGGIE G D, SOMMADOSSI J P, CROSS D S, et al. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma,urine, and bile[J]. Cancer Res, 1987,47(8):2203-2206.
[9]　　 YOSHIDA Y, OGURA K, HIRATSUKA A ,et al. 5-Fluorouracil chemotherapy for dihydropyrimidine dehydrogenase-deficient patients: potential of the doseescalation method[J] . Anticancer Res, 2015,35(9): 4881-4887.
[10] 陆建伟, 高长明, 吴建中, 等. 亚甲基四氢叶酸还原 酶基因 C677T 多态性与胃癌患者对 5-FU 化疗敏感 性的关系[J]. 癌症, 2004, 23(8):958-962. 　　 LU Jianwei, GAO Changming, WU Jianzhong, , et al. Relationship of methylenetetrahydrofolate reductase C677T polymorphism and chemosensitivity to 5-fluorouracil in gastric carcinoma[J]. Chinese Journal of Cancer, 2004, 23(8):958-962.
[11] LIU Haizhou, LIU Hui, ZHOU Zhiyi , et al . Herbal formula Huang Qin Ge Gen Tang enhances 5-fluorouracil antitumor activity through modulation of the E2F1/TS pathway:[J]. Cell Communication & Signaling, 2018, 16(1):7.
[12] DURINIKOVA E, PLAVA J, TYCIAKOVA S, et al. Cytotoxic response of 5-fluorouracil-resistant cells to gene- and cell-directed enzyme/prodrug treatment.[J]. Cancer Gene Therapy, 2018,25(11/12):285-299.
[13] KONO S, CHEN Kun. Genetic polymorphisms of methylenetetrahydrofolate reductase and colorectal cancer and adenoma.[J]. Cancer Science, 2005, 96(9):535-542.
[14] EHSANI M, IMANI A, MORAVVEJI A. Prevalence of factor V leiden, MTHFR C677T and MTHFR A1298C polymorphisms in patients with deep vein thrombosis in Central Iran [J]. Molecular Biology Reports, 2018, 45(4):621-624.
[15] 刘佳宁, 李磊, 崔永霞, 等. 晚期结直肠癌患者5- 氟 尿嘧啶药代动力学参数AUC 与不良反应及近期疗效的相关性分析[J]. 中华 实用诊断与治疗杂志, 2016, 30(3):301-303. 　　 LIU Jianing, LI Lei, CUI Yongxia, et al. Correlation of pharmacokinetic parameter AUC with adverse reactions and short-term effect of 5-fluorouracil in patients with advanced colorectal cancer[J]. Journal of Chinese Practical Diagnosis and Therapy, 2016, 30(3):301-303.
[16] 鞠颖慧，周琰，彭颖斐, 等. 液相色谱串联质谱检 测血浆5- 氟尿嘧啶方法的建立及其临床应用[J]. 中 华医学杂志, 2016, 96(10):817-821. 　　 JU Yinghui, ZHOU Yan, PENG Yingfei, et al. Establishment and clinical application of liquid chromatography-tandem mass spectrometric method for simultaneous determination of plasma 5-fluorouracil[J]. National Medical Journal of China, 2016, 96(10):817-821.
[17] 周铄. 不同5-FU 剂量的FOLFIRI 方案联合西妥昔 单抗治疗转移性结直肠癌的疗效观察[J]. 医学理论 与实践, 2017, 30(1):11-13. 　　 ZHOU Shuo. The curative effect observation of different dosages 5-FU FOLFIRI scheme combined with cetuximab in metastatic colorectal cancer[J]. The Journal of Medical Theory and Practice, 2017, 30(1):11-13.
[18] 朱达军. 奥沙利铂+ 亚叶酸钙(cf)+ 氟尿嘧啶(5FU) 化疗的不良反应[J]. 中外医疗, 2016, 35(32):127- 128,155. 　　 ZHU Dajun. Oxaliplatin + Calcium leucovorin (cf) + Fluorouracil (5 FU) the side effects of chemotherapy[J]. China Foreign Medical Treatment, 2016, 35(32):127- 128,155.
[19] WANG Jin, XU Lijuan, XIA Hongmiao, et al. Association of MTHFR C677T gene polymorphism with metabolic syndrome in a Chinese population: a case-control study [J]. Journal of International Medical Research, 2018, 46(7):2658-2669.
[20] SOHN K J, SMIRNAKIS F, MOSKOVITZ D N, et al. Effects of folylpolyglutamate synthetase modulation on chemosensitivity of colon cancer cells to 5-fluorouracil and methotrexate.[J]. Gut, 2004, 53(12):1825-1831.
[21] 寇军燕, 洪卫, 洪丹, 等. MTHFR C677T 基因多态 性与晚期非小细胞肺癌化疗不良反应的关系[J]. 中 国癌症杂志, 2014, 24(3):197-202. 　　 KOU Junyan, HONG Wei, HONG Dan, et al. Relationship between MTHFR C677T gene polymorphisms and chemotherapy side effects in advanced non-small cell lung cancer[J]. China Oncology, 2014, 24(3):197-202.

备注/Memo

备注/Memo:
收稿日期：2020-02-07　修回日期：2020-03-01基金项目：上海青年临床医技人才（临床检验专业）培养资助计划（沪医卫基[2016]05 号）；国家自然科学基金面上项目（81572064， 　　　　　81772263）；中山医院管理院内基金（2019ZSGL09）；2017 年上海市“上海青年临床医技人才（临床检验专业）培养资助计划； 　　　　　国家自然科学基金青年基金（81902139）；上海市临床重点专科建设项目（医学检验科）。 作者简介：周琰（1981-），女，学士，副主任技师，研究方向：分子诊断学，E-mail：zhou.yan3@zs-hospital.sh.cn。 通信作者：郭玮，主任技师，E-mail：guo.wei@zs-hospital.sh.cn。
更新日期/Last Update: 2020-07-20